Monopar Therapeutics to conduct a 1-5 reverse stock split on August 13th.
Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company developing cancer treatment therapeutics, will undergo a 1-5 reverse stock split on Aug 13th. The firm's lead product candidate, Validive, is in Phase 2b/3 clinical trials for chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients. The split will adjust shareholder holdings post-Aug 12th close.
August 10, 2024
3 Articles